Middle East and Africa Respiratory Inhalers Market Report and Forecast 2024-2032

Middle East and Africa Respiratory Inhalers Market Report and Forecast 2024-2032

Middle East and Africa Respiratory Inhalers Market Report and Forecast 2024-2032

Middle East and Africa Respiratory Inhalers Market Size

The global respiratory inhalers market was valued at USD 33.5 billion in 2023, with the Middle East and Africa holding a significant market share. The market is driven by the rising burden of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). It is expected to grow at a CAGR of 4.9% during the forecast period of 2024-2032, with the values likely to attain USD 53.9 billion by 2032.

Middle East and Africa Respiratory Inhalers Market Outlook

• Recent data reveals that the prevalence of asthma is relatively high in the United Arab Emirates, affecting 10-15% of the adult population along with 20-25% of school-aged children. Similarly, in South Africa, it causes substantial loss of life.
• One of the major Middle East and Africa respiratory inhalers market trends is the rising investments in the development of eco-friendly inhaler technology. In April 2024 , Mundipharma, in collaboration with Vectura announced plans to reformulate an established flutiform® pressurized metered-dose inhaler (pMDI), aiming to reduce the product’s carbon footprint by incorporating an environmentally friendly propellant.
• The market share is influenced by the growing preference for combination inhaler therapies which consist of multiple medications in a single inhaler device, thereby driving the demand for combination inhalers.

Middle East and Africa Respiratory Inhalers Market Analysis

Respiratory inhalers are used to administer medication directly into the lungs to treat respiratory conditions. These devices contain different types of medications such as bronchodilators (to relax the muscles in the airways), corticosteroids (to reduce inflammation), and combination therapies (containing both bronchodilators and corticosteroids). There is a growing shift towards the development of combination inhaler therapies which consists of multiple medications in a single inhaler device, driving the demand for combination inhalers (aerosol or dry powder inhalers). Further, the rising advancements in digital inhaler technologies such as smart inhalers are expected to significantly contribute to the Middle East and Africa respiratory inhalers market growth.

The market is influenced by rising burden of respiratory conditions that directly impact the demand for effective respiratory inhalers. Recent data reveals that the prevalence of asthma is relatively high in the United Arab Emirates, accounting for 10-15% of the adult population and 20-25% of school-aged children. Similarly, it is estimated that over 10-15% of adults and 20% of children in South Africa are affected by asthma along with a high number of deaths caused by the condition. This increasing prevalence of respiratory diseases, attributed to factors such as smoking, air pollution, and changing lifestyle patterns, is anticipated to fuel the Middle East and Africa respiratory inhalers market demand in the coming years.

One of the major market trends include an increasing focus on the development of eco-friendly inhaler technologies in the region. For instance, in April 2024 , Mundipharma (a global healthcare company with a strong presence in the Middle East and Africa) in collaboration with contract development and manufacturing organization (CDMO) Vectura announced plans to reformulate an established flutiform® pressurized metered-dose inhaler (pMDI) for asthma treatment. The remodelling aims at reducing the product’s carbon footprint by incorporating an environment friendly propellant. The growing efforts toward the advancement of respiratory inhaler technology with a lower environmental impact is projected to elevate the market value.

Middle East and Africa Respiratory Inhalers Market Segmentation  

The report offers a detailed analysis of the market based on the following segments:

Market Breakup by Product Type

• Dry Powdered Inhalers
• Metered Dose Inhalers
• Soft Mist Inhalers
• Nebulizers

o Jet Nebulizers

o Ultrasonic Nebulizers

o Mesh Nebulizers

Market Breakup by Type

• Conventional Inhalers
• Smart Inhalers

Market Breakup by Indication

• Asthma
• COPD

Market Breakup by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Market Breakup by End Use

• Hospitals
• Clinics
• Homecare Settings
• Others

Market Breakup by Countries

• Saudi Arabia
• United Arab Emirates
• Nigeria
• South Africa
• Others

Leading Players in the Middle East and Africa Respiratory Inhalers Market

The key features of the market report include funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• AstraZeneca Plc
• Beximco Pharmaceuticals Ltd.
• Boehringer Ingelheim International GmbH
• Cipla Ltd
• GSK Plc
• Koninklijke Philips NV
• OMRON Corp
• Pari Respiratory Equipment, Inc.
• Teva Pharmaceutical Industries Ltd
• OPKO Health, Inc.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

FAQs

• What is the Middle East and Africa respiratory inhalers market forecast outlook for 2024-2032?

The Middle East and Africa respiratory inhalers market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 5.4% during the forecast period of 2024-2032 and is likely to reach a market value of USD 53.9 billion by 2032.

• What are the major factors aiding the Middle East and Africa respiratory inhalers market demand?

The rising burden of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) is fuelling the demand for the market.

• What are the major Middle East and Africa respiratory inhalers market trends?

One of the significant trends in the market is the rising investments in the development of sustainable respiratory inhalers. In April 2024, Mundipharma, in collaboration with Vectura announced plans to reformulate an established flutiform® pressurized metered-dose inhaler (pMDI) with the aim to reduce the product’s carbon footprint by incorporating an environmentally friendly propellant.

• What is the market segmentation based on the product?

Based on the product, the market is segmented into dry powder inhalers, metered dosed inhalers, soft mist inhalers, and nebulizers. The nebulizer category is further bifurcated into jet nebulizers ultrasonic nebulizers, and mesh nebulizers.

• What is the market breakup by type?

By type, the market is divided into conventional inhalers and smart inhalers.

• What is the market segmentation based on the indication?

The market breakup by indication includes asthma and COPD.

• What are the major end users of respiratory inhalers?

End users of the market are hospitals, clinics, and homecare settings, among others.

• What is the market segmentation by countries?

The market segmentation by countries includes Saudi Arabia, the United Arab Emirates, Nigeria, and South Africa, among others.

• Who are the key players involved in the Middle East and Africa respiratory inhalers market?

The key players in the market are AstraZeneca Plc, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, Cipla Ltd, GSK Plc, Koninklijke Philips NV, OMRON Corp, Pari Respiratory Equipment, Inc., Teva Pharmaceutical Industries Ltd., and OPKO Health, Inc.

Meta description

The Middle East and Africa respiratory inhalers market is poised for growth, driven by the expansion of the global market, which was valued at USD 33.5 billion in 2023 and is projected to grow at a CAGR of 5.4% during the forecast period of 2024-2032.

*Please Note:* The report will take 7 business days to complete, after order confirmation.